Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DYANAVEL XR 20 vs ADDERALL 30
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.
Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.
FDA-approved: Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.,Off-label: Treatment-resistant depression, narcolepsy (though individual components are approved for narcolepsy, DYANAVEL XR as a specific formulation is not).
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.
Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day
Terminal elimination half-life: 6-8 hours (stable metabolite). Clinical context: Twice-daily dosing typical due to pharmacokinetic profile; extended half-life compared to immediate-release amphetamine.
Terminal elimination half-life: d-amphetamine 10-13 hours, l-amphetamine 13-15 hours; in adults (children: 6-8 hours). The longer half-life allows for once-daily dosing.
Amphetamine is metabolized primarily by CYP2D6 and also by CYP2C19 and CYP3A4 via deamination, oxidation, and conjugation. The active metabolites include 4-hydroxyamphetamine and norephedrine. Genetic polymorphisms in CYP2D6 may affect metabolism and drug levels.
Primarily hepatic via CYP2D6, with minor contributions from CYP1A2, CYP2B6, and CYP3A4.
Renal: 90% (unchanged drug and metabolites, primarily hippuric acid). Fecal/biliary: <1%.
Approximately 30-40% of a dose is excreted unchanged in urine; the remainder is metabolized primarily by oxidative deamination and aromatic hydroxylation. Biliary/fecal elimination accounts for less than 5%.
15-40% bound to albumin.
Approximately 20-25% bound to plasma proteins, mainly albumin and alpha-1-acid glycoprotein.
3-5 L/kg (indicates extensive tissue distribution; crosses blood-brain barrier).
Vd: 3-4 L/kg (approximately 210-280 L for a 70 kg adult). This indicates extensive tissue distribution and penetration into the central nervous system.
Oral (extended-release): 95% (high bioavailability; minimal first-pass metabolism).
Oral immediate-release: approximately 75-100%; oral extended-release: approximately 94% relative to immediate-release. Food does not significantly affect absorption but may delay peak concentration.
GFR 15-29 m L/min: maximum 40 mg/day; GFR <15 m L/min or dialysis: not recommended.
GFR 30-89 m L/min: no adjustment; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use
Ages 6-17: initial 10 mg once daily; may increase by 5-10 mg weekly to max 30 mg/day for ages 6-12, max 40 mg/day for ages 13-17.
Children 3-5 years: initial 2.5 mg orally once daily; increase by 2.5 mg weekly; usual range 2.5-20 mg/day. Children ≥6 years: initial 5 mg once or twice daily; increase by 5 mg weekly; usual range 5-40 mg/day in divided doses
Initiate at 10 mg once daily; lower doses may be required due to renal function decline; monitor for cardiac effects.
Initiate at 2.5 mg orally once or twice daily; titrate slowly; monitor for cardiovascular effects, insomnia, and weight loss
DYANAVEL XR has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events. It should be prescribed cautiously, especially in patients with a history of substance abuse.
Amphetamines have a high potential for abuse and dependence. Misuse may cause sudden death or serious cardiovascular events.
Serious cardiovascular events: Sudden death, stroke, and myocardial infarction have been reported, especially in patients with structural cardiac abnormalities or other serious heart problems.,Blood pressure and heart rate increase: Monitor vital signs regularly.,Psychiatric adverse events: May exacerbate pre-existing psychosis, mania, or aggression; caution in patients with bipolar disorder or history of psychosis.,Seizures: May lower seizure threshold; use cautiously in patients with seizure disorders.,Peripheral vasculopathy: Including Raynaud's phenomenon; monitor for digital changes.,Serotonin syndrome: Risk when co-administered with serotonergic drugs.,Growth suppression: Long-term use may slow growth in children; monitor height and weight.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities,Increased blood pressure and heart rate,Psychiatric adverse events including exacerbation of pre-existing psychosis, mania, or aggressive behavior,Serotonin syndrome risk when co-administered with serotonergic drugs,Long-term suppression of growth in children,Seizure risk in patients with history of seizures,Peripheral vasculopathy including Raynaud's phenomenon,Visual disturbances due to mydriasis
Hypersensitivity to amphetamine or any component of the formulation.,Concurrent use or within 14 days of monoamine oxidase inhibitors (MAOIs) due to risk of hypertensive crisis.,Hyperthyroidism.,Agitated states.,Glaucoma.,History of drug abuse.,Cardiovascular disease: Moderate to severe hypertension, advanced arteriosclerosis, symptomatic coronary artery disease, structural heart abnormalities, cardiomyopathy, serious arrhythmias, or other serious cardiac conditions.
Advanced arteriosclerosis,Symptomatic cardiovascular disease,Moderate to severe hypertension,Hyperthyroidism,Known hypersensitivity to amphetamines,Agitated states,History of drug abuse,During or within 14 days of MAO inhibitor use,Glaucoma
Avoid high-fat meals around the time of administration as they may delay absorption and reduce peak concentration. Limit caffeine intake (coffee, tea, soda, energy drinks) as it can exacerbate nervousness, insomnia, and cardiovascular effects. No specific food restrictions otherwise.
Avoid high-fat meals as they delay absorption; avoid acidic foods (e.g., citrus) and vitamin C supplements within 1 hour of dosing as they decrease absorption; limit caffeine and other stimulants to avoid additive cardiovascular effects.
Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 41 times the maximum recommended human dose of 20 mg/day (based on mg/m²) produced no teratogenic effects; however, increased neonatal mortality and reduced growth were observed at maternally toxic doses. In humans, retrospective studies have reported a higher incidence of premature delivery, low birth weight, and withdrawal symptoms (e.g., dysphoria, agitation, lassitude) in neonates exposed to amphetamines during the third trimester. There is also a potential risk for cardiovascular malformations if used in the first trimester. Therefore, the drug should be used only if the potential benefit justifies the potential risk to the fetus.
Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased risk of premature delivery, low birth weight, and neonatal withdrawal symptoms (e.g., dysphoria, agitation, lassitude). Chronic use may lead to neonatal toxicity.
Amphetamines are excreted into human milk. The milk-to-plasma concentration ratio for amphetamine is approximately 1.8 to 5.9. A nursing infant would receive 4-10% of the maternal weight-adjusted dose. There are reports of irritability, poor feeding, and decreased weight gain in infants exposed to amphetamines via breast milk. The manufacturer recommends discontinuing nursing or the drug, taking into account the importance of the drug to the mother.
Excreted in breast milk. M/P ratio unknown. Potential for stimulant effects in infant (e.g., irritability, poor feeding, insomnia). Caution advised; consider alternative feeding methods.
Pregnancy may alter the pharmacokinetics of amphetamines due to increased plasma volume, renal blood flow, and hepatic metabolism. The elimination half-life may be shortened, requiring dose adjustments. However, no specific dosing guidelines are established for pregnancy. Use the lowest effective dose, and monitor clinical response and tolerability. Postpartum doses may need to be reduced to pre-pregnancy levels.
No established dosing guidelines. Due to increased plasma volume and clearance, dose may need titration to clinical effect, but avoid supratherapeutic doses. Use lowest effective dose.
For patients with attention deficit hyperactivity disorder (ADHD), initiate at 20 mg once daily in the morning; may increase by 10 mg weekly to a maximum of 60 mg/day. Contains immediate-release and extended-release beads; avoid crushing or chewing. Monitor for hypertension, tachycardia, and growth suppression in children. Use with caution in patients with pre-existing cardiovascular disease or seizure disorder. Do not co-administer with MAOIs or within 14 days of discontinuing an MAOI.
For ADHD: start low, go slow; monitor weight and height in children; avoid late doses to prevent insomnia; check for abuse/diversion; screen for bipolar disorder and hypertension; consider urine drug screen before prescribing; avoid MAOIs within 14 days; use with caution in seizure disorders and glaucoma.
Take exactly as prescribed, usually once daily in the morning to avoid insomnia.,Swallow capsules whole; do not crush, chew, or open them.,Avoid alcohol and caffeine-containing products as they may worsen side effects.,Inform your doctor of all other medications, including over-the-counter drugs and supplements.,Report any chest pain, shortness of breath, or fainting immediately.,For children, height and weight will be monitored during treatment.,Do not stop abruptly without consulting your doctor; dosage may need to be tapered.
Take exactly as prescribed; do not crush or chew capsules.,Take the first dose upon waking; avoid afternoon/evening doses.,May cause insomnia, loss of appetite, or nervousness.,Do not drink alcohol while taking this medication.,Report chest pain, palpitations, shortness of breath, or mood changes.,Store securely; do not share medication with others.,Regular blood pressure and heart rate monitoring is necessary.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DYANAVEL XR 20 vs ADDERALL 30, answered by our medical review team.
DYANAVEL XR 20 is a CNS Stimulant that works by DYANAVEL XR is a central nervous system (CNS) stimulant. The mode of action is primarily through blockade of the reuptake of norepinephrine and dopamine into the presynaptic neuron, increasing their levels in the extraneuronal space. It also releases these monoamines from storage sites. The dextroamphetamine component is more potent than amphetamine in inhibiting norepinephrine reuptake, while the amphetamine component is more potent in inhibiting dopamine reuptake.. ADDERALL 30 is a CNS Stimulant that works by Adderall contains mixed amphetamine salts that increase synaptic levels of dopamine and norepinephrine by inhibiting their reuptake and promoting release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DYANAVEL XR 20 and ADDERALL 30 depend on the specific clinical indication. These are both CNS Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DYANAVEL XR 20 is: Initial 20 mg orally once daily in the morning, with or without food; may increase by 10 mg weekly to maximum 60 mg/day.. The standard adult dose of ADDERALL 30 is: Initial: 5 mg orally once or twice daily; increase by 5 mg increments weekly; usual maintenance: 20-30 mg daily in divided doses; maximum: 40 mg/day. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DYANAVEL XR 20 and ADDERALL 30 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DYANAVEL XR 20 is classified as Category C. Pregnancy Category C. There is no adequate and well-controlled study in pregnant women. In animal reproduction studies, amphetamine (dextroamphetamine/amphetamine) at doses up to 4. ADDERALL 30 is classified as Category C. Pregnancy category C. First trimester: No well-controlled studies, but potential for congenital malformations not definitively established. Second and third trimesters: Increased r. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.